• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet appoints Elizabeth Weatherman to board of directors

February 9, 2022 By Sean Whooley

InsuletInsulet (NSDQ:PODD) announced that Elizabeth (Bess) Weatherman was appointed to its board of directors.

Weatherman — a veteran dealmaker in the health technology space — will stand for election by stockholders at the company’s 2022 annual meeting and has been named to the board’s Compensation Committee.

Acton, Massachusetts–based Insulet said in a news release that Weatherman currently serves as a special limited partner of Warburg Pincus LLC, having originally joined in 1988 with a primary focus on investment activities in the healthcare sector. She led the firm’s healthcare group from 2008 to 2015.

Weatherman has twice been named to the Forbes Midas List in recognition of her position as one of the 100 most highly regarded dealmakers in the venture capital industry, while she also received the 2014 Women of Power and Influence Award from the National Organization of Women. She currently serves as a director of Nevro, Silk Road Medical and Vapotherm.

“On behalf of the board, I am excited to welcome Bess to Insulet,” Timothy Scannell, chairman of Insulet’s board of directors, said in the release. “Bess brings extensive experience in healthcare and is highly regarded in the medical technology and private equity industries. Her strong leadership and strategic and governance perspectives will add tremendous value as we continue to advance our growth initiatives.”

The company also announced that, following six years of service to the Insulet board of directors, board member David Lemoine will retire in May.

“We thank Dave for his leadership and significant contributions to Insulet,” Scannell said. “Dave has been a steadfast partner to the board, and we wish him well in his retirement.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel Tagged With: Insulet, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS